• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    1/25/23 4:31:07 PM ET
    $CALA
    $CDTX
    $FNA
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CALA alert in real time by email

    Gainers

    • GT Biopharma (NASDAQ:GTBP) shares increased by 7.4% to $0.91 during Wednesday's after-market session. The market value of their outstanding shares is at $33.0 million.
    • Science 37 Hldgs (NASDAQ:SNCE) stock rose 6.79% to $0.46. The market value of their outstanding shares is at $53.5 million.
    • Marker Therapeutics (NASDAQ:MRKR) shares rose 5.74% to $0.41. The market value of their outstanding shares is at $34.4 million.
    • TScan Therapeutics (NASDAQ:TCRX) shares increased by 5.55% to $1.9. The market value of their outstanding shares is at $45.7 million.
    • Minerva Surgical (NASDAQ:UTRS) stock rose 5.29% to $0.4. At the close, Minerva Surgical's trading volume reached 1.0 million shares. This is 135.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.0 million.
    • Hillstream BioPharma (NASDAQ:HILS) stock rose 5.21% to $0.63. The market value of their outstanding shares is at $7.2 million.

    Losers

    • Ocuphire Pharma (NASDAQ:OCUP) stock decreased by 30.9% to $2.6 during Wednesday's after-market session. This security traded at a volume of 304.2K shares come close, making up 123.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $54.0 million.
    • Paragon 28 (NYSE:FNA) stock declined by 10.31% to $18.01. The market value of their outstanding shares is at $1.3 billion.
    • MediciNova (NASDAQ:MNOV) stock fell 7.15% to $2.34. The company's market cap stands at $114.7 million.
    • Incannex Healthcare (NASDAQ:IXHL) shares fell 7.05% to $3.3. The market value of their outstanding shares is at $201.1 million.
    • Cidara Therapeutics (NASDAQ:CDTX) stock fell 6.26% to $1.2. At the close, Cidara Therapeutics's trading volume reached 5.0 million shares. This is 842.3% of its average volume over the last 100 days. The company's market cap stands at $85.9 million.
    • Calithera Biosciences (NASDAQ:CALA) shares fell 5.01% to $0.41. This security traded at a volume of 121.6K shares come close, making up 52.5% of its average volume over the last 100 days. The company's market cap stands at $1.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CALA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALA
    $CDTX
    $FNA
    $GTBP

    CompanyDatePrice TargetRatingAnalyst
    Medicinova Inc
    $MNOV
    3/16/2026$10.00Buy
    H.C. Wainwright
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    TScan Therapeutics Inc.
    $TCRX
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    6/18/2025$41.00Buy
    H.C. Wainwright
    More analyst ratings

    $CALA
    $CDTX
    $FNA
    $GTBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MediciNova with a new price target

    H.C. Wainwright initiated coverage of MediciNova with a rating of Buy and set a new price target of $10.00

    3/16/26 8:42:01 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cidara Therapeutics downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Cidara Therapeutics from Outperform to Sector Perform

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded Cidara Therapeutics from Overweight to Equal-Weight

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $73,552 worth of shares (81,732 units at $0.90) and bought $71,974 worth of shares (80,069 units at $0.90) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    12/23/25 6:17:28 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $99,999,988 worth of shares (2,272,727 units at $44.00) (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    6/30/25 4:56:56 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    SEC Filings

    View All

    SEC Form PRE 14A filed by TScan Therapeutics Inc.

    PRE 14A - TScan Therapeutics, Inc. (0001783328) (Filer)

    4/7/26 4:30:19 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GT Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    4/7/26 7:05:14 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by TScan Therapeutics Inc.

    8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    4/2/26 7:30:07 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

    Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form

    9/26/23 12:02:02 PM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Amello Jason

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    1/22/26 5:52:24 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Macbeath Gavin

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    1/22/26 5:48:44 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Dworak Leiden

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    1/22/26 5:30:20 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TSca

    4/8/26 7:00:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

    MELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The Company has utilized the buyback program opportunistically in the past, however had not actively repurchased shares in recent periods. The decision to reinitiate buyback activity reflects the Board of Directors' view that the Company's current market valuation does not accurately reflect the strength of its balance sheet, clinical prog

    3/27/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

    MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundation's Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026. The partnership reflects the Company's commitment to the broader sleep medicine community as it con

    3/25/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $CALA
    $CDTX
    $FNA
    $GTBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CALA
    $CDTX
    $FNA
    $GTBP
    Financials

    Live finance-specific insights

    View All

    Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to JanssenBARDA award to support expanded manufacturing and clinical development of CD388FDA granted Breakthrough Therapy designation to CD388Conference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak® platform

    11/6/25 4:07:08 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

    Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call and webcast scheduled for Monday, November 3, 8:00 a.m. Eastern Time WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology comp

    11/3/25 6:30:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

    SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, November 6, 2025Time:5:00 PM Eastern TimeUnited States:1-844-825-9789International:1-412-317-5180Conferen

    10/23/25 4:05:00 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care